Giuseppe Lauletta
YOU?
Author Swipe
View article: Biologics and small molecules for psoriasis: current and future progress
Biologics and small molecules for psoriasis: current and future progress Open
View article: Baricitinib for adult atopic dermatitis: real-world effectiveness, safety, and response predictors
Baricitinib for adult atopic dermatitis: real-world effectiveness, safety, and response predictors Open
In this real-world study, baricitinib provided substantial long-term effectiveness with a favorable safety profile in moderate-to-severe AD, and atopic comorbidities emerged as a predictor of optimal clinical response at week 16.
View article: The Use of JAK Inhibitors in Elderly Patients with Moderate-to-Severe Atopic Dermatitis: A Narrative Review of Clinical and Real-World Evidence
The Use of JAK Inhibitors in Elderly Patients with Moderate-to-Severe Atopic Dermatitis: A Narrative Review of Clinical and Real-World Evidence Open
Background: Atopic dermatitis (AD) in elderly patients presents unique clinical challenges due to comorbidities, polypharmacy, and an increased risk of adverse events. Janus kinase inhibitors (JAKis) have emerged as effective oral treatmen…
View article: Safety and Effectiveness of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis Who Smoke: a 2-Year Real-Life Multicenter Study
Safety and Effectiveness of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis Who Smoke: a 2-Year Real-Life Multicenter Study Open
View article: Effectiveness and Safety of Dupilumab and Tralokinumab for Treating Atopic Dermatitis and Pruritic Skin Disorders in Oncological Patients: A Narrative Review
Effectiveness and Safety of Dupilumab and Tralokinumab for Treating Atopic Dermatitis and Pruritic Skin Disorders in Oncological Patients: A Narrative Review Open
Patients with active or past cancer are typically excluded from clinical trials of new medications, complicating the evaluation of cancer progression or recurrence risks in these patients setting. The potential use of biologic drugs like d…
View article: Successful Use of Photodynamic Therapy for Treatment of Palbociclib-Induced Periorificial Dermatitis
Successful Use of Photodynamic Therapy for Treatment of Palbociclib-Induced Periorificial Dermatitis Open
View article: Dermatologic immune‐related adverse events: It is time for a game change!
Dermatologic immune‐related adverse events: It is time for a game change! Open
Data are reported in the current paper.
View article: A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab [Corrigendum]
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab [Corrigendum] Open
[This corrects the article DOI: 10.2147/CCID.S447123.].
View article: Management of Psoriasis Patients with Serious Infectious Diseases
Management of Psoriasis Patients with Serious Infectious Diseases Open
The management of patients affected by moderate-to-severe psoriasis may be challenging, in particular in patients with serious infectious diseases [tuberculosis (TB), hepatitis B and C, HIV, COVID-19]. Indeed, these infections should be ru…
View article: Risk Factors for Psoriasis Flares: A Narrative Review
Risk Factors for Psoriasis Flares: A Narrative Review Open
Psoriasis is a chronic inflammatory cutaneous disease with multifactorial pathogenesis involving both genetic and environmental factors as well as the innate and acquired immune response. Several triggering factors may exacerbate or worsen…
View article: The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials Open
Psoriasis pathogenesis is influenced by genetic factors and characterized by a complex interplay between genetic predisposition and various environmental triggers. These triggers set off metabolic processes involving inflammation, cell sig…
View article: Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities
Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities Open
Psoriasis is now considered a systemic disease, and several comorbidities have been described such as cardiovascular diseases, neurologic and psychiatric disorders, chronic inflammatory bowel disease, psoriatic arthritis, etc. Regarding ca…
View article: A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab Open
Psoriasis is a chronic inflammatory cutaneous disease, affecting up to 3% of the worldwide population. Several clinical phenotypes can be distinguished. Among these, erythrodermic psoriasis (EP) is a rare and severe variant (less than 3% o…
View article: A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years
A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years Open
Background: Dupilumab has been shown to be a safe and effective drug for the treatment of atopic dermatitis (AD) in children from 6 months to 11 years in randomized clinical trials. Aim: The aim of this real-life study was to determ…